Valuation Clinuvel Pharmaceuticals Limited Nasdaq

Stocks

Market Closed - Nasdaq 20:30:00 29/10/2026 GMT			5-day change	1st Jan Change
5.150 ^USD	+1.58%		+2.39%	-39.27%

02:58am	Clinuvel Pharmaceuticals Seeks European Marketing Approvals for Neuracthel Instant Product	MT
10-19	Disc Medicine's late-stage win clears path for approval of sun-allergy pill	RE

Data adjusted to current consolidation scope

Fiscal Period: June	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	733.7	883.5	769.8	520.3	518.4	369.6	-	-
Change	-	20.4%	-12.87%	-32.41%	-0.36%	-28.7%	-	-
Enterprise Value (EV) ¹	612.2	726.6	585.9	296.2	309.1	86.53	54.02	16.53
Change	-	18.69%	-19.37%	-49.45%	4.37%	-72.01%	-37.57%	-69.4%
P/E	36.8x	30.3x	22x	14.5x	15.4x	10.6x	10.2x	7.18x
PBR	5.84x	5.37x	3.79x	2.17x	1.91x	1.21x	1.09x	0.95x
PEG	-	0.6x	1.2x	5.06x	-2.21x	3.19x	2.71x	0.2x
Capitalization / Revenue	11.2x	11.3x	8.73x	5.48x	5.51x	3.91x	3.68x	2.75x
EV / Revenue	9.32x	9.28x	6.64x	3.12x	3.29x	0.92x	0.54x	0.12x
EV / EBITDA	16.4x	19.5x	12x	6.84x	8.09x	2.29x	1.37x	0.29x
EV / EBIT	16.7x	20x	12.3x	7.03x	8.31x	2.36x	1.42x	0.29x
EV / FCF	15.5x	20.2x	18.6x	7.26x	8.76x	2.37x	1.34x	0.3x
FCF Yield	6.44%	4.94%	5.37%	13.8%	11.4%	42.3%	74.4%	338%
Dividend per Share ²	0.04	0.05	0.05	0.05	0.05	0.0547	0.0592	0.0832
Rate of return	0.27%	0.28%	0.33%	0.48%	0.49%	0.75%	0.81%	1.13%
EPS ²	0.403	0.591	0.698	0.718	0.668	0.6902	0.7162	1.021
Distribution rate	9.93%	8.46%	7.16%	6.96%	7.49%	7.92%	8.26%	8.15%
Net sales ¹	65.72	78.32	88.18	95.02	94.02	94.47	100.4	134.4
EBITDA ¹	37.44	37.2	48.95	43.3	38.2	37.75	39.3	57.96
EBIT ¹	36.68	36.41	47.81	42.12	37.21	36.65	38.13	56.47
Net income ¹	20.88	30.6	35.64	36.17	33.92	34.94	36.32	51.72
Net Debt ¹	-121.5	-156.8	-183.9	-224.1	-209.3	-283.1	-315.6	-353.1
Reference price ²	14.850	17.880	15.370	10.380	10.280	7.330	7.330	7.330
Nbr of stocks (in thousands)	49,410	49,410	50,083	50,124	50,428	50,428	-	-
Announcement Date	30/08/22	29/08/23	28/08/24	27/08/25	27/08/26	-	-	-

¹AUD in Million²AUD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	40.35x	13.85x	30.26x	0.5%	1,224B
JOHNSON & JOHNSON	40.28x	6.76x	19.02x	1.94%	662B
ABBVIE INC.	38.08x	8.51x	17.61x	2.36%	514B
ROCHE HOLDING AG	21.65x	5.25x	13.07x	2.49%	388B
MERCK & CO., INC.	106.67x	5.95x	25.48x	2.33%	361B
NOVARTIS AG	22.86x	5.89x	14.22x	2.75%	302B
ASTRAZENECA PLC	22.82x	4.6x	13.15x	1.92%	271B
AMGEN INC.	29.23x	7.45x	13.34x	2.19%	249B
GILEAD SCIENCES, INC.	-47.64x	7.37x	28.55x	1.99%	205B
Average	30.48x	7.29x	19.41x	2.05%	464.09B
Weighted average by Cap.	36.66x	8.71x	21.55x	1.73%